View Older Stories View More Recent Stories

Oct 24, 2022 07:33AM Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting
Oct 10, 2022 06:00AM Exact Sciences schedules third quarter 2022 earnings call
Sep 12, 2022 05:22AM Exact Sciences (EXAS) Reports Additional Data from Multi-Cancer Early Detection Approach
Sep 10, 2022 04:33AM Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress
Sep 1, 2022 06:00AM Exact Sciences to participate in September investor conference
Aug 2, 2022 04:05PM Exact Sciences Announces Second Quarter 2022 Results
Aug 2, 2022 04:05PM Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients
Aug 2, 2022 04:01PM MDxHealth (MDXH) Acquires Oncotype DX GPS Prostate Cancer Business from Exact Sciences (EXAS)
Aug 1, 2022 06:00AM Exact Sciences to participate in August investor conference
Jul 8, 2022 03:49PM Exact Sciences (EXAS) Applauds Proposed CMS Change to Colorectal Cancer Screening Policy
Jul 8, 2022 03:47PM Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy
Jul 8, 2022 06:00AM Exact Sciences schedules second quarter 2022 earnings call
Jun 21, 2022 07:18AM Ultima Genomics and Exact Sciences (EXAS) enter long-term supply agreement
Jun 21, 2022 06:00AM Ultima Genomics and Exact Sciences enter long-term supply agreement aimed at improving patient access to genomic testing by driving down sequencing costs
May 27, 2022 08:50AM Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022
May 27, 2022 06:00AM Exact Sciences to participate in June investor conferences
May 2, 2022 06:00AM Exact Sciences to participate in May investor conference
Apr 28, 2022 09:00AM Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
Apr 26, 2022 04:05PM Exact Sciences Announces First Quarter 2022 Results
Apr 8, 2022 06:00AM Exact Sciences schedules first quarter 2022 earnings call
Mar 7, 2022 09:00AM Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer
Mar 1, 2022 08:30AM Diversey Appoints Katherine S. Zanotti to its Board of Directors
Mar 1, 2022 08:30AM Diversey Appoints Katherine S. Zanotti to its Board of Directors
Feb 28, 2022 06:00AM Exact Sciences to participate in March investor conferences
Feb 22, 2022 04:05PM Exact Sciences Announces Fourth Quarter 2021 Results
Feb 8, 2022 06:00AM Exact Sciences schedules fourth quarter 2021 earnings call
Feb 1, 2022 06:00AM Exact Sciences to participate in February investor conferences
Jan 18, 2022 05:19PM Exact Sciences (EXAS) Reports Data Showing Improved Accuracy of Second-generation Cologuard Test
Jan 18, 2022 05:17PM Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients
Jan 10, 2022 05:45AM Exact Sciences (EXAS) Enters Licensing Agreement with OncXerna
Jan 10, 2022 05:44AM Exact Sciences (EXAS) Guides Q4 Revenues of $472M-$475M
Jan 10, 2022 05:44AM Exact Sciences (EXAS) Acquires PreventionGenetics for $190M Cash and Stock
Jan 9, 2022 07:00PM Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients
Jan 9, 2022 07:00PM Exact Sciences Announces Preliminary Fourth Quarter 2021 Results
Jan 9, 2022 07:00PM Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients
Jan 3, 2022 06:00AM Exact Sciences to participate in J.P. Morgan Healthcare Conference
Dec 8, 2021 11:30AM New Data Presented at SABCS® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making
Dec 1, 2021 05:06PM Exact Sciences (EXAS) Announces Publication in NEJM Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test
Dec 1, 2021 05:05PM Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
Nov 23, 2021 09:10AM Exact Sciences (EXAS) Announces New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients
Nov 23, 2021 09:08AM New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients
Nov 18, 2021 08:30AM Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection
Nov 16, 2021 02:32PM Scipher Medicine® Appoints Sam Asgarian, M.D., MBA Chief Medical Officer
Nov 2, 2021 04:05PM Exact Sciences announces third quarter 2021 results
Nov 1, 2021 06:00AM Exact Sciences to participate in November investor conferences
Oct 25, 2021 05:33PM New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening
Oct 21, 2021 01:00AM MDxHealth Provides Q3-2021 Business Update
Oct 8, 2021 06:00AM Exact Sciences schedules third quarter 2021 earnings call
Sep 14, 2021 06:00AM Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients
Sep 1, 2021 06:00AM Exact Sciences to participate in September investor conferences
View More Recent Stories View Older Stories